Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of …
Abstract Objectives The 2018 Canadian Network for Mood and Anxiety Treatments
(CANMAT) and International Society for Bipolar Disorders (ISBD) guidelines provided …
(CANMAT) and International Society for Bipolar Disorders (ISBD) guidelines provided …
Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data
SM Stahl, S Laredo… - Therapeutic Advances in …, 2020 - journals.sagepub.com
Cariprazine is one of the newest dopamine-serotonin partial agonists, also known as
'atypical'second generation antipsychotics. Originally approved for acute and maintenance …
'atypical'second generation antipsychotics. Originally approved for acute and maintenance …
[HTML][HTML] Taiwan consensus on biological treatment of bipolar disorder during the acute, maintenance, and mixed phases: The 2022 update
Background Bipolar disorder is a mood dysregulation characterized by recurrent symptoms
and episodes of mania, hypomania, depression, and mixed mood. The complexity of treating …
and episodes of mania, hypomania, depression, and mixed mood. The complexity of treating …
[HTML][HTML] The efficacy of lumateperone on symptoms of depression in bipolar I and bipolar II disorder: Secondary and post hoc analyses
RS McIntyre, S Durgam, SG Kozauer, R Chen… - European …, 2023 - Elsevier
A recent Phase 3, randomized, double-blind, placebo-controlled study established that
lumateperone 42-mg monotherapy significantly improved symptoms of depression in …
lumateperone 42-mg monotherapy significantly improved symptoms of depression in …
Efficacy of cariprazine in bipolar I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies
M Patel, R Jain, M Tohen, V Maletic… - International Clinical …, 2021 - journals.lww.com
Patients who experience bipolar depression have diverse demographic and clinical
characteristics that have the potential to impact treatment. The efficacy of cariprazine in …
characteristics that have the potential to impact treatment. The efficacy of cariprazine in …
[HTML][HTML] A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression
WR Earley, M Burgess, L Rekeda, A Hankinson… - Journal of Affective …, 2020 - Elsevier
Background The safety and efficacy of cariprazine, a dopamine D 3-preferring D 3/D 2
receptor partial agonist and serotonin 5-HT 1A receptor partial agonist, was evaluated in 4 …
receptor partial agonist and serotonin 5-HT 1A receptor partial agonist, was evaluated in 4 …
[HTML][HTML] Reducing addiction in bipolar disorder via hacking the dopaminergic system
H Grunze, R Csehi, C Born, Á Barabássy - Frontiers in Psychiatry, 2021 - frontiersin.org
The dopaminergic system plays a central and decisive role in substance use disorder
(SUD), bipolar disorder (BD), and possibly in a subgroup of patients with refractory …
(SUD), bipolar disorder (BD), and possibly in a subgroup of patients with refractory …
Advances in the psychopharmacotherapy of bipolar disorder type I
A Sleem, RS El-Mallakh - Expert Opinion on Pharmacotherapy, 2021 - Taylor & Francis
ABSTRACT INTRODUCTION Research into the pharmacologic management of bipolar type
I illness continues to progress. AREAS COVERED Randomized clinical trials performed with …
I illness continues to progress. AREAS COVERED Randomized clinical trials performed with …
[HTML][HTML] Treatment of symptom clusters in schizophrenia, bipolar disorder and major depressive disorder with the dopamine D3/D2 preferring partial agonist …
B Batinic, I Ristic, M Zugic, DS Baldwin - Frontiers in Psychiatry, 2021 - frontiersin.org
Cariprazine is currently approved for the treatment of patients with schizophrenia (USA and
EU), and for manic, depressive, and episodes with mixed features in bipolar I disorder …
EU), and for manic, depressive, and episodes with mixed features in bipolar I disorder …
[PDF][PDF] Cariprazine for Treating Schizophrenia, Mania, Bipolar Depression, and Unipolar Depression: A Review of Its Efficacy
This drug review presents a comprehensive review of Cariprazine, a medication that
received FDA approval in 2015 for treating schizophrenia and bipolar disorder. The paper …
received FDA approval in 2015 for treating schizophrenia and bipolar disorder. The paper …